原始出處紀錄
決策級主要結果 (Topline)
Verastem：RAMP 301 第三期初步數據預計於 2027 年年中公布
2026 年 3 月的企業簡報指出，RAMP 301 確證性第三期試驗將比較 avutometinib + defactinib 與研究者選擇療法，用於復發性 LGSOC，預計於 2027 年年中公布初步數據。此數據旨在確認 RAMP 201 的結果，並可能擴大 AVMAPKI FAKZYNJA CO-PACK 的核准適應症，不限 KRAS 突變狀態。
關鍵事實
- 申報時間
- 2026年3月4日 下午09:15
- 事件
- 主要結果 (Topline)
- 方向
- 中性
- 來源
- SEC 8-K
- 可信度
- 有出處
來源摘錄
EX-99.1 2 tm267866d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Delivering Novel Therapies for RAS/MAPK Pathway-Driven Cancers C O R P O R A T E P R E S E N T A T I O N M A R C H 2 0 2 6 2 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements about, among other things, Verastem Oncology’s (the “Company”) programs and product candidates, strategy, future plans and prospects, including statements related to the approval and commercialization of AVMAPKIFAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) as a treatment for adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant-type (mt) recurrent Low-Grade Serous Ovarian Cancer (LGSOC), the expected outcome and benefits of collaborations, including with GenFleet Therapeutics (Shanghai), Inc